HEALTHSTORY 1126· JUNE 24, 2026

WHO-Backed Clinical Trial to Test Remdesivir and MBP-134 Against Bundibugyo Ebolavirus in DRC

A clinical trial set to begin next week in the Democratic Republic of the Congo will test Gilead Sciences' antiviral drug remdesivir and MappBio's monoclonal antibody MBP-134 against the Bundibugyo ebolavirus, the World Health Organization…

NDNewsDialy Desk2 MIN READ

SOURCE

statnews.com

← PREVIOUS STORY 1125Asia Technology Stocks Mostly Rebound After Global Rout; Samsung Gains 9%NEXT STORY 1127 →Federal Judge Blocks Texas Prosecutors From Subpoenaing Transgender Patient Records at New York Hospitals

Keep reading

More from the desk.

06HEALTH

EU legal adviser hands pharma a win on wastewater costs

Pharmaceutical and cosmetics companies across Europe may be off the hook for the largest share of a continent-wide water cleanup effort, after a legal adviser to the EU's top court recommended striki

health2 MIN

07HEALTH

FDA clears first drug to target muscle loss in spinal muscular atrophy

Federal regulators approved a drug on Friday for spinal muscular atrophy, a rare neurological condition where the nerve cells that signal muscles to move gradually deteriorate. The drug, Isembyld, is the first approved therapy to directly…

health2 MIN

15HEALTH

AstraZeneca's breast cancer pill camizestrant fails first-line trial

A breast cancer drug failed its largest clinical test, a result that could limit how widely the medicine is prescribed. First-line therapy is the term for the initial drug doctors try after a patient's cancer advances, before other options…

health2 MIN

Tomorrow · 06:00

Start tomorrow already ahead.

Five stories, a two-minute read, zero noise — the world before your first coffee.

Get the 6AM brief Back to the desk